logo
Plus   Neg
Share
Email

NeuroRx, Relief, Quantum Leap To Include ZYESAMI In I-SPY COVID-19 Trial

NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (RLFTF) announced Monday that the companies signed a Clinical Trial Participation Agreement with Quantum Leap Healthcare Collaborative or QLHC for the inclusion of ZYESAMI (RLF-100: aviptadil) in the I-SPY COVID-19 Clinical Trial.

QLHC is the sponsor of the I-SPY COVID-19 Trial, a platform trial that is assessing multiple drugs for the treatment of patients with Critical COVID-19 who are hospitalized or in intensive care units.

ZYESAMI will be included as one of the first drugs targeting Respiratory Failure in critically ill COVID-19 patients.

The inclusion of ZYESAMI in the I-SPY COVID-19 Trial follows a request from the U.S. Department of Health and Human Services and the Department of Defense for investigational drugs capable of targeting the most acutely ill patients with COVID-19.

ZYESAMI has been granted Fast Track designation by the U.S. Food & Drug Administration for the treatment of Critical COVID-19 in patients with Respiratory Failure.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow. Pfizer Inc. (PFE) and OPKO Health Inc. (OPK) announced Friday that the European Medicines Agency or EMA has validated for review the Marketing Authorization Application for somatrogon. Pfizer expects a decision from the European Commission in 2022. The company said somatrogon is a long-acting recombinant... German telecom giant Deutsche Telekom AG reported Friday strong growth in fourth-quarter profit mainly driven by T-Mobile US results following the takeover of the competitor Sprint. Looking ahead for fiscal 2021, the company projects higher adjusted EBITDA AL, a key earnings metric.
RELATED NEWS
Follow RTT